Mobile

A clinical study to explore the efficacy and tolerability of IMGN529 taken together with Rituximab in patients with diffuse large B-cell lymphoma (DLBCL) or other forms of non-Hodgkin's lymphoma (NHL)...

Update Il y a 4 ans
Reference: EUCTR2015-004061-87

A clinical study to explore the efficacy and tolerability of IMGN529 taken together with Rituximab in patients with diffuse large B-cell lymphoma (DLBCL) or other forms of non-Hodgkin's lymphoma (NHL) who have stopped responding or have failed to respond to current cancer treatments

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

- Characterize the safety and tolerability of IMGN529 in combination with rituximab when administered IV every three weeks to adult patients with relapsed and/or refractory NHL - Determine the anti-tumor activity of IMGN529 in combination with rituximab when administered IV every three weeks to adult patients with relapsed and/or refractory NHL

Inclusion criteria

  • Patients with Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma and Other Forms of Non-Hodgkin’s Lymphoma

Links